Live
FierceBiotechGalmed acquires Colospan in $4.5M deal as it eyes $6B GI dx marketBioPharma DiveMerck, Gilead report mixed outcomes in key lung cancer, HIV studiesEndpoints NewsA different approach to lowering healthcare costsCellmRNA 3′ UTRs chaperone intrinsically disordered regions to control protein activityClinical OMICsBeyond the Genome: Five Emerging Leaders in Epigenetics DiagnosticsBioPharma DiveStealthy startup Treeline plans a reverse merger10x Genomics Blog10x Genomics Acquires Proteintech Genomics to Expand Single-Cell Proteomics Portfolio - citybizEndpoints NewsHow K Health moved AI chatbots into hospitals10x Genomics News10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group - BioSpaceEndpoints NewsLilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drugEndpoints NewsTrodelvy misses in lung cancer, but Gilead and Merck have an HIV successFierceBiotechADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal program
Curiosis Inc. 20 avr. 2026

Operating margin % of Curiosis, Inc. – KRX:494120 - TradingView

Operating margin % of Curiosis, Inc. – KRX:494120 - TradingView

Original
Contenu indisponible. Consultez la source originale.